GALECTIN THERAPEUTICS INC (GALT) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:GALT • US3632252025

2.69 USD
-0.11 (-3.93%)
Last: Feb 9, 2026, 09:57 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

0

Overall GALT gets a fundamental rating of 0 out of 10. We evaluated GALT against 523 industry peers in the Biotechnology industry. Both the profitability and financial health of GALT have multiple concerns. GALT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year GALT has reported negative net income.
  • In the past year GALT has reported a negative cash flow from operations.
  • GALT had negative earnings in each of the past 5 years.
  • GALT had a negative operating cash flow in each of the past 5 years.
GALT Yearly Net Income VS EBIT VS OCF VS FCFGALT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • GALT has a Return On Assets of -291.04%. This is amonst the worse of the industry: GALT underperforms 91.01% of its industry peers.
Industry RankSector Rank
ROA -291.04%
ROE N/A
ROIC N/A
ROA(3y)-203.75%
ROA(5y)-152.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GALT Yearly ROA, ROE, ROICGALT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

  • GALT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GALT Yearly Profit, Operating, Gross MarginsGALT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • GALT has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for GALT has been increased compared to 5 years ago.
  • The debt/assets ratio for GALT is higher compared to a year ago.
GALT Yearly Shares OutstandingGALT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
GALT Yearly Total Debt VS Total AssetsGALT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -64.69, we must say that GALT is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -64.69, GALT is doing worse than 91.78% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -64.69
ROIC/WACCN/A
WACCN/A
GALT Yearly LT Debt VS Equity VS FCFGALT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

  • GALT has a Current Ratio of 0.09. This is a bad value and indicates that GALT is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of GALT (0.09) is worse than 94.26% of its industry peers.
  • GALT has a Quick Ratio of 0.09. This is a bad value and indicates that GALT is not financially healthy enough and could expect problems in meeting its short term obligations.
  • GALT has a worse Quick ratio (0.09) than 94.26% of its industry peers.
Industry RankSector Rank
Current Ratio 0.09
Quick Ratio 0.09
GALT Yearly Current Assets VS Current LiabilitesGALT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 19.18% over the past year.
EPS 1Y (TTM)19.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • GALT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.76% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.24%
EPS Next 2Y20.41%
EPS Next 3Y11.76%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GALT Yearly Revenue VS EstimatesGALT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 100M 200M 300M 400M 500M
GALT Yearly EPS VS EstimatesGALT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • GALT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GALT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GALT Price Earnings VS Forward Price EarningsGALT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GALT Per share dataGALT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.41%
EPS Next 3Y11.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • GALT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GALECTIN THERAPEUTICS INC

NASDAQ:GALT (2/9/2026, 9:57:50 AM)

2.69

-0.11 (-3.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-30
Inst Owners16.05%
Inst Owner Change1.83%
Ins Owners19.28%
Ins Owner Change-2.46%
Market Cap173.42M
Revenue(TTM)N/A
Net Income(TTM)-37.44M
Analysts82.86
Price Target11.22 (317.1%)
Short Float %10.49%
Short Ratio8.73
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.3%
Min EPS beat(2)-15.86%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)5.16%
Min EPS beat(4)-16.42%
Max EPS beat(4)26.47%
EPS beat(8)4
Avg EPS beat(8)-0.57%
EPS beat(12)6
Avg EPS beat(12)-1.18%
EPS beat(16)9
Avg EPS beat(16)3.35%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)83.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0
BVpS-1.92
TBVpS-1.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -291.04%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-203.75%
ROA(5y)-152.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.09
Quick Ratio 0.09
Altman-Z -64.69
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.78%
EPS Next Y34.24%
EPS Next 2Y20.41%
EPS Next 3Y11.76%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.65%
EBIT Next 3Y7.92%
EBIT Next 5YN/A
FCF growth 1Y13.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.74%
OCF growth 3YN/A
OCF growth 5YN/A

GALECTIN THERAPEUTICS INC / GALT FAQ

What is the fundamental rating for GALT stock?

ChartMill assigns a fundamental rating of 0 / 10 to GALT.


What is the valuation status for GALT stock?

ChartMill assigns a valuation rating of 0 / 10 to GALECTIN THERAPEUTICS INC (GALT). This can be considered as Overvalued.


How profitable is GALECTIN THERAPEUTICS INC (GALT) stock?

GALECTIN THERAPEUTICS INC (GALT) has a profitability rating of 0 / 10.


What is the expected EPS growth for GALECTIN THERAPEUTICS INC (GALT) stock?

The Earnings per Share (EPS) of GALECTIN THERAPEUTICS INC (GALT) is expected to grow by 34.24% in the next year.